# A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

> **NCT03733353** · PHASE1 · COMPLETED · sponsor: **Evelo Biosciences, Inc.** · enrollment: 204 (actual)

## Conditions studied

- Psoriasis
- Atopic Dermatitis

## Interventions

- **DRUG:** EDP1815
- **DRUG:** Placebo oral capsule
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT03733353
- **Lead sponsor:** Evelo Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-19
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733353, "A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03733353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*